Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tiopronin
Therapeutic Area : Nephrology
Study Phase : Approved
Recipient : Cycle Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment
Details : Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. It is indicated for cystinuria.
Brand Name : Tiopronin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2024
Lead Product(s) : Tiopronin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Recipient : Cycle Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Study Phase : Approved
Recipient : Cycle Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
New U.S. Product ORMALVI Tablets Launches for Primary Periodic Paralysis Treatment
Details : Ormalvi (dichlorphenamide) is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Brand Name : Ormalvi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 08, 2024
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Recipient : Cycle Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Brand Name : Keveyis-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2023
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?